我国生物医药行业数字化转型瓶颈及应对建议
Bottlenecks of digital transformation in China's biopharmaceutical industry and corresponding suggestions
王晓玲1
作者信息
- 1. 中国信息通信研究院信息化与工业化融合研究所,北京 100191
- 折叠
摘要
作为我国战略性新兴产业,生物医药行业面临内外交困的局面,数字化转型成为逆境突围的必由之路.然而,当前生物医药行业数字化转型受限于数据基础不足、政策监管相对滞后、缺少针对性的评估体系以及复合背景人才短缺四大瓶颈,转型进展相对落后.建议从统一数据标准、建立公共数据资源体系、创新监管模式、建设转型评估体系以及培育人才队伍等方面入手,加快生物医药行业数字化转型.
Abstract
As an emerging emerging industry in China,the biopharmaceutical industry is facing difficulties both internally and externally.Digital transformation has become a necessary path for overcoming adversities.However,the digital transformation of the biopharmaceutical industry is currently constrained by four major bottlenecks:insufficient data foundation,relatively lagging policy regulation,lack of targeted evaluation systems,and shortage of compound talents.The progress of transformation is relatively backward.It is recommended to accelerate the digital transformation of the biopharmaceutical industry by unifying data standards,establishing public data resource systems,innovating regulatory models,constructing transformation evaluation systems,and cultivating talent teams.
关键词
数字化转型/生物医药行业/制药/瓶颈/建议Key words
digital transformation/biopharmaceutical industry/pharmacy/bottleneck/suggestion引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据